IMNM — Immunome Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1472012 ·
Last close
$28.01
Market Cap
$3.18B
52W High
$30.06
52W Low
$17.83
ADV30
1,118,816
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -59,331,000 | -53,839,000 | 619,792,000 | 582,693,000 | 31,106,000 |
| Dec 2025 | 0 | — | -72,861,000 | -69,900,000 | 683,188,000 | 653,482,000 | 48,845,000 |
| Sep 2025 | 0 | — | -60,138,000 | -57,457,000 | 299,377,000 | 272,639,000 | 35,458,000 |
| Jun 2025 | 4,015,000 | — | -46,478,000 | -43,397,000 | 296,290,000 | 143,876,000 | 27,020,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-196,502,000
Investing CF
$43,698,000
Financing CF
$477,994,000
CapEx
$-18,036,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.15
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-782,003,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-238,808,000
Pretax Income TTM
$-224,593,000
Interest Exp TTM
—
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-257,687,008
Free Cash Flow
$-143,656,624
Enterprise Value
$2,666,053,376
Total Cash
$519,996,000
Total Debt
$4,740,000
Shares Out
113,577,629
Trailing EPS
$-2.48
Book Value
$4.63
ROE
-64.0%
ROA
-37.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,941,000 | -224,113,000 | -212,394,000 | 683,188,000 | 48,845,000 | — | -190,919,000 |
| Dec 2024 | 9,041,000 | -153,456,000 | -292,963,000 | 240,241,000 | 59,076,000 | — | -110,794,000 |
| Dec 2023 | 14,018,000 | -28,728,000 | -106,806,000 | 148,540,000 | 28,658,000 | — | -7,568,000 |
| Dec 2022 | 0 | -36,901,000 | -36,896,000 | 24,046,000 | 7,393,000 | — | -28,690,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.48
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MBX | MBX Biosciences, Inc. | $3.20B | $66.39 | — |
| NAMS | NewAmsterdam Pharma Co N.V. | $3.21B | $26.85 | — |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.11B | $24.78 | — |
| IRON | Disc Medicine, Inc. | $3.11B | $80.94 | — |
| QURE | uniQure N.V. | $3.29B | $47.46 | — |
News headlines (Yahoo Finance, 1h cache)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-06 20:02 · Yahoo
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
2026-07-20 11:30 · Yahoo
What This Immunome Sale Means a Day Before a Big FDA Milestone
2026-07-12 21:04 · Yahoo
Immunome Stock Up 32% in a Month: Here's What You Should Know
2026-07-10 14:40 · Yahoo
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
2026-07-08 11:30 · Yahoo
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
2026-06-11 11:30 · Yahoo
Immunome (IMNM) Is Down 12.7% After Phase 3 Varegacestat Data And FDA NDA Filing - Has The Bull Case Changed?
2026-06-05 02:13 · Yahoo
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
2026-05-30 12:00 · Yahoo
What Offers Immunome (IMNM) a Compelling Investment Opportunity?
2026-05-18 12:54 · Yahoo
Immunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid Tumors
2026-05-12 00:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.